| Autor: |
Robinson PA; Pfizer Central Research, Groton, Connecticut 06340., Knirsch AK, Joseph JA |
| Jazyk: |
angličtina |
| Zdroj: |
Reviews of infectious diseases [Rev Infect Dis] 1990 Mar-Apr; Vol. 12 Suppl 3, pp. S349-63. |
| DOI: |
10.1093/clinids/12.supplement_3.s349 |
| Abstrakt: |
Fluconazole therapy was evaluated prospectively in patients with serious fungal infections who failed to respond to or could not tolerate conventional antifungal therapy. Patients were enrolled if they had a life-threatening fungal infection and conventional therapy had failed to eradicate the infection, had caused serious toxic reactions, or was contraindicated. Patients were treated with 200 mg/day, a dosage that could be increased to 400 mg/d if the initial response was not satisfactory. AIDS was the underlying risk factor in 65% of 232 patients evaluated in the study and in 85% of 151 patients with cryptococcal infection. Fifty-eight patients had active cryptococcal infection; 74% had a satisfactory clinical response, and 75% of 44 patients became culture-negative. Patients with inactive infection had a relapse rate of 4.5/1,000 patient-weeks. Twenty-three of 30 patients with coccidioidal infection and 10 of 14 patients with candidiasis or another mycosis were clinically improved. Five patients (2%) discontinued fluconazole therapy because of adverse effects possibly attributable to therapy. Fluconazole may be effective in the treatment of serious fungal infections in patients who cannot continue conventional antifungal therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
